ArticleFrontiers in immunology2023

Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.

Ying-Tao Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.